Clinical Trial Update: Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing entecavir and lamivudine to prevent hepatitis B reactivation in patients with non-Hodgkin lymphoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Non-hodgkin Lymphoma

Drugs mentioned

• Entecavir (Baraclude) (Entecavir)
• Lamivudine (Epivir) (lamivudine)

Snippet

Sponsor: Fudan University | Conditions: Non-Hodgkin Lymphoma, Hepatitis B Reactivation | Phase 2 | Status: UNKNOWN